EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of influenza virus infection in mice by pulmonary administration of a spray dried antiviral drug

Rick Heida, Paulo H Jacob Silva, Renate Akkerman, Jill Moser, Jacqueline de Vries-Idema, Aurélien Bornet, Sujeet Pawar, Francesco Stellacci, Henderik W Frijlink, Anke L W Huckriede, Wouter L J Hinrichs

European Journal of Pharmaceutics and Biopharmaceutics · 2024

DOI: 10.1016/j.ejpb.2024.114507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2024. Verfasst von Rick Heida und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, the Netherlands. Hauptthemen laut MEDLINE: Antiviral Agents, Orthomyxoviridae Infections, beta-Cyclodextrins, Dry Powder Inhalers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Werner Siemens Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increasing resistance to antiviral drugs approved for the treatment of influenza urges the development of novel compounds. Ideally, this should be complemented by a careful consideration of the administration route. 6'siallyllactosamine-functionalized β-cyclodextrin (CD-6'SLN) is a novel entry inhibitor that acts as a mimic of the primary attachment receptor of influenza, sialic acid. In this study, we aimed to develop a dry powder formulation of CD-6'SLN to assess its in vivo antiviral activity after administration via the pulmonary route. By means of spray drying the compound together with trileucine, a dispersion enhancer, we created a powder that retained the antiviral effect of the drug, remained stable under elevated temperature conditions and performed well in a dry powder inhaler. To test the efficacy of the dry powder drug against influenza infection in vivo, infected mice were treated with CD-6'SLN using an aerosol generator that allowed for the controlled administration of powder formulations to the lungs of mice. CD-6'SLN was effective in mitigating the course of the disease compared to the control groups, reflected by lower disease activity scores and by the prevention of virus-induced IL-6 production. Our data show that CD-6'SLN can be formulated as a stable dry powder that is suitable for use in a dry powder inhaler and is effective when administered via the pulmonary route to influenza-infected mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsOrthomyxoviridae Infectionsbeta-CyclodextrinsDry Powder InhalersLungAnimalsMiceAdministration, InhalationPowdersMice, Inbred BALB CFemaleSpray DryingAerosolsDogs

Stichwörter der Autor:innen

Aerosol scienceAntiviral drugsBroad spectrumCyclodextrinDry powder inhalerEntry inhibitorIn vivoInfluenza virusInhalationIntratracheal administrationPulmonary drug deliveryRespiratory virusesRodentsSpray drying

Substanzen

Antiviral Agentsbeta-CyclodextrinsPowdersAerosols

Autor:innen und Institutionen

  • Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, the Netherlands.
  • Institute of Materials, Ecole Polytechnique Fédérale de Lausanne, Lausanne 1015 Switzerland.
  • Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, the Netherlands.
  • Department of Critical Care, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands; Department of Pathology and Medical Biology, University of Groningen, Universi…
  • Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, 9713 AV Groningen, the Netherlands. Electronic address: w.l.j.hinrichs@rug.nl.

Förderung

  • Swiss National Science Foundation
  • Werner Siemens Foundation

Zitieren

APA

Heida, R., Jacob Silva, P. H., Akkerman, R., Moser, J., de Vries-Idema, J., Bornet, A., Pawar, S., Stellacci, F., Frijlink, H. W., Huckriede, A. L. W., & Hinrichs, W. L. J. (2024). Inhibition of influenza virus infection in mice by pulmonary administration of a spray dried antiviral drug. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2024.114507

Vancouver

Heida R, Jacob Silva PH, Akkerman R, Moser J, de Vries-Idema J, Bornet A, et al. Inhibition of influenza virus infection in mice by pulmonary administration of a spray dried antiviral drug. European Journal of Pharmaceutics and Biopharmaceutics. 2024. doi:10.1016/j.ejpb.2024.114507

BibTeX
@article{Heida2024,
  author = {Heida, Rick and Jacob Silva, Paulo H and Akkerman, Renate and Moser, Jill and de Vries-Idema, Jacqueline and Bornet, Aurélien and Pawar, Sujeet and Stellacci, Francesco and Frijlink, Henderik W and Huckriede, Anke L W and Hinrichs, Wouter L J},
  title = {Inhibition of influenza virus infection in mice by pulmonary administration of a spray dried antiviral drug},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2024},
  doi = {10.1016/j.ejpb.2024.114507}
}
Kostenlos starten →